Brent Logan, PhD

Brent R. Logan, PhD

Director & Professor

Locations

Biostatistics

Contact Information

Education

PhD, Northwestern University, Evanston, IL, 2001
MS, Northwestern University, Evanston, IL, 1998
BS, Vanderbilt University, Nashville, TN, 1996

Research Experience

Multiple Comparison Procedures

Research Interests

Dr. Brent Logan joined the Division of Biostatistics in the Summer of 2001. He has methodological research interests in multiple comparison procedures, clinical trial design, and survival analysis. Research in multiple testing includes methods for analyzing multiple endpoints in clinical trials, analysis of dose-response studies, and multiplicity adjustment in functional MRI studies. His interests in clinical trial design include randomized phase 2 clinical trials and biologic assignment trials in bone marrow transplant studies. Recent work in survival analysis has focused on inference for competing risks and multistate models using pseudo-value regression, analysis in the presence of crossing survival curves, and methods for the analysis of complex bone marrow transplant data. He is a biostatistician for the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) and the Center for International Blood and Marrow Transplant Research (CIBMTR), as well as a statistical consultant for the National Marrow Donor Program.

Curriculum Vitae

Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.

(Farhadfar N, Hsu JW, Logan BR, Sees JA, Chitphakdithai P, Sugrue MW, Abdel-Azim H, Anderlini PN, Bredeson C, Chhabra S, Diaz MA, Ganguly S, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Lynch DK, Murthy HS, Olsson RF, Papari M, Przepiorka D, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Yared JA, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR.) Blood Adv. 2020 Feb 25;4(4):706-716 PMID: 32092138 PMCID: PMC7042992 SCOPUS ID: 2-s2.0-85082202343 02/25/2020
Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

(Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW.) Blood Adv. 2020 Feb 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.

(Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML.) Blood. 2020 Jan 09;135(2):97-107 PMID: 31738834 PMCID: PMC6952830 SCOPUS ID: 2-s2.0-85077761109 11/19/2019
Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey.

(Chan AY, Leiding JW, Liu X, Logan BR, Burroughs LM, Allenspach EJ, Skoda-Smith S, Uzel G, Notarangelo LD, Slatter M, Gennery AR, Smith AR, Pai SY, Jordan MB, Marsh RA, Cowan MJ, Dvorak CC, Craddock JA, Prockop SE, Chandrakasan S, Kapoor N, Buckley RH, Parikh S, Chellapandian D, Oshrine BR, Bednarski JJ, Cooper MA, Shenoy S, Davila Saldana BJ, Forbes LR, Martinez C, Haddad E, Shyr DC, Chen K, Sullivan KE, Heimall J, Wright N, Bhatia M, Cuvelier GDE, Goldman FD, Meyts I, Miller HK, Seidel MG, Vander Lugt MT, Bacchetta R, Weinacht KG, Andolina JR, Caywood E, Chong H, de la Morena MT, Aquino VM, Shereck E, Walter JE, Dorsey MJ, Seroogy CM, Griffith LM, Kohn DB, Puck JM, Pulsipher MA, Torgerson TR.) Front Immunol. 2020;11:239 PMID: 32153572 PMCID: PMC7046837 03/11/2020
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

(Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME.) J Clin Oncol. 2019 Dec 20:JCO1903011 PMID: 31860405 12/21/2019
Molecular Correlates of Socioeconomic Status and Clinical Outcomes Following Hematopoietic Cell Transplantation for Leukemia.

(Knight JM, Rizzo JD, Wang T, He N, Logan BR, Spellman SR, Lee SJ, Verneris MR, Arevalo JMG, Cole SW.) JNCI Cancer Spectr. 2019 Dec;3(4):pkz073 PMID: 31763620 PMCID: PMC6859844 11/26/2019
Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy.

(Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M.) Br J Haematol. 2020 Mar 02 PMID: 32124435 SCOPUS ID: 2-s2.0-85080995146 03/04/2020
Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.

(Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, Ahmed IA, Anderlini PN, Bredseon C, Chhabra S, Dandoy CE, Diaz MA, Farhadfar N, Ganguly S, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Olsson RF, Savan BN, Schears R, Seo S, Solh M, Spitzer T, Steinberg A, Sugure M, Warkentin P, Wingard JR.) Biol Blood Marrow Transplant. 2020 Feb 20 PMID: 32088366 02/24/2020
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.

(Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD.) JAMA Oncol. 2019 Dec 12 PMID: 31830234 PMCID: PMC6990739 SCOPUS ID: 2-s2.0-85076620276 12/13/2019
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.

(Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E.) Biol Blood Marrow Transplant. 2019 Nov 19 PMID: 31756536 SCOPUS ID: 2-s2.0-85077165933 11/23/2019
Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.

(Ballen K, Logan BR, Chitphakdithai P, Kuxhausen M, Spellman SR, Adams A, Drexler RJ, Duffy M, Kemp A, King R, Babic A, Delaney C, Karanes C, Kurtzberg J, Petz L, Scaradavou A, Shpall EJ, Smith C, Confer DL, Miller JP.) Biol Blood Marrow Transplant. 2019 Nov 19 PMID: 31756539 SCOPUS ID: 2-s2.0-85077166820 11/23/2019
Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults.

(Majhail NS, Mau LW, Chitphakdithai P, Denzen EM, Joffe S, Lee SJ, LeMaistre CF, Loberiza F, Parsons SK, Repaczki-Jones R, Robinett P, Douglas Rizzo J, Murphy E, Logan B, Le-Rademacher J.) Bone Marrow Transplant. 2019 Nov 18 PMID: 31740767 SCOPUS ID: 2-s2.0-85075369259 11/20/2019